Hemophilia Treatment Drugs Market is expected to reach US$ 25.2 Bn Globally by 2024: Transparency Market Research

Hemophilia is a rare disease in which blood does not clot normally. It is a rare bleeding disorder which is mostly inherited but may also be caused by spontaneous gene mutations. Hemophilia mostly affects males. One among 50,000 males is born with hemophilia every year. The indications such as internal bleeding, external bleeding etc. are treated with hemophilia drugs. Growth in the incidence rate of hemophilia disorders across the globe is expected to surge the number of patients, who will require diagnosis and treatment, hence will contribute towards market growth. Hemophilia is a disease with many variations in its severity level. The severity level of hemophilia A and B depends upon the percentage of coagulation factors present in the patient’s blood. Depending on clotting factors present within the blood; hemophilia can be mild, moderate or severe. The patients with severe hemophilia A have less than 1% factor VIII activity; compared to the people who do not have hemophilia have 100% activity of Factor VIII.

The global Hemophilia Treatment Drugs Market was valued at US$ 15,852.5 Mn in 2015 and is expected to increase at a CAGR of 5.4% during the forecast period from 2016 to 2024 to reach US$ 25,192.8 Mn in 2024.

Based on product type, the hemophilia treatment drugs market has been categorized into Recombinant coagulation factor concentrates, Plasma derived coagulation factor concentrates, Desmopressin and Antifibrinolytic agents. By disease indication the hemophilia treatment drugs are classified into hemophilia A, hemophilia B and others. On the basis of distribution channel the hemophilia treatment drugs market is segmented into hospital pharmacies, retail pharmacies, and E-commerce.

The major geographies analyzed in the report include North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. Additionally these major five regions further have been segmented into major country markets. This report provides the market estimations at country level for the U.S., Canada, U.K., Germany, France, Italy, Spain, Brazil, Mexico, China, Japan, India, Australia and others.

Geographically, the market for hemophilia treatment drugs is dominated by North America in 2015 and is expected to contribute significantly during the forecast period from 2016 to 2024.  In the U.S. major prevalence of hemophilia A is a key factor in development and progression of the market. In 2015 U.S was the country with highest number of hemophilia patients according to World Federation of hemophilia. Followed by Europe, which held the second largest share of the hemophilia treatment drugs market in terms of revenue in 2015. Europe will account for around 37.0% market share by the end of the forecast period. Rising prevalence of hemophilia diseases in low and middle- income countries the Asia-Pacific and Latin America are expected to serve great opportunity for the hemophilia treatment drugs market during the forecast period. Increasing population, high cost drugs and rising awareness levels regarding the bleeding diseases are likely to further drive the growth of this market. In North America, the U.S. attracts more than 90% market share while Canada contribute for a very minor part. Europe’s hemophilia treatment drug market is dominated by the U.K. In Asia Pacific the hemophilia treatment drugs market is anticipated to be dominated by China and Japan at the end of the forecast period.

Download PDF Brochure of Report – http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1900

Key players operating in the global hemophilia treatment drugs market are Novo Nordisk A/S, CSL Behring, F. Hoffmann-La Roche Ltd., Bayer AG, Pfizer Inc., Biotest AG, Kedrion Biopharma Inc., Octapharma AG, Shire Plc, and Biogen.

The global hemophilia treatment drugs market is segmented as follows:

  • Global Hemophilia Treatment Drugs Market Revenue, by Product type
    • Recombinant coagulation factor concentrates
      • Factor VIII
      • Factor IX
      • Combination
    • Plasma derived coagulation factor concentrates
      • Factor VIII
      • Factor IX
      • Combination
    • Desmopressin
    • Antifibrinolytic agents
  • Global Hemophilia Treatment Drugs Market Revenue, by Disease indication
    • Hemophilia A
    • Hemophilia B
    • Others
  • Global Hemophilia Treatment Drugs Market Revenue, by Distribution channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • E-commerce
  • Global Hemophilia Treatment Drugs Market Revenue, by Geography
    • North America
      • US
      • Canada
    • Europe
      • Germany
      • France
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East and Africa
      • Saudi Arabia
      • South Africa
      • Rest of Middle East & Africa

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: http://www.transparencymarketresearch.com

VN:F [1.9.22_1171]
Rating: 0.0/5 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)

No comments.

Leave a Reply

You must be logged in to post a comment.